Strategic Fit Leverage RELiZORB for pediatric and neonatal enteral feeding settings to address fat malabsorption in cystic fibrosis and other GI disorders, presenting a clear value proposition to hospitals, pediatric clinics, and long-term acute care facilities.

Expansion Opportunities Target emerging use cases and regulatory expansions around immobilized lipase technology in enteral nutrition, including potential adjacencies in digestive disorders and rare diseases to broaden product adoption in hospital and home-care channels.

Clinical Validation Highlight published pivotal trial data and post-market updates to support evidence-based selling; engage clinical teams for in-service trainings and case studies to drive formulary approvals and payer engagement.

Strategic Partnerships Explore collaborations with large medical device and pharmaceutical distributors, pediatric specialty networks, and insurer networks to accelerate market access and co-market RELiZORB in targeted care pathways.

Growth Momentum Capitalize on leadership appointments and ongoing FDA clearance expansions as signals of credibility; align sales efforts with product lifecycle milestones and upcoming clinical data releases to time strategic outreach and budget cycles.